RPL35A是參與胃癌發(fā)生發(fā)展的關(guān)鍵啟動(dòng)子

2021年9月，中國(guó)人民解放軍總醫(yī)院**醫(yī)療中心普外科高級(jí)科(Senior Department of General Surgery, The First Medical Center of Chinese, PLA General Hospital, Fuxin Road, No. 28, Haidian District,Beijing 100853, China) Canrong Lu老師研究團(tuán)隊(duì)在《Cancer Cell International》上發(fā)表論文：

“RPL35A is a key promotor involved in the development and progression of gastric cancer”

“RPL35A是參與胃癌發(fā)生發(fā)展的關(guān)鍵啟動(dòng)子”

Abstract：

Background: RPL35A has been reported to work as a biomarker in tumor angiogenesis. However, little work has been performed on the expression level and functional importance of RPL35A in gastric cancer (GC).

Methods: The protein expression level of RPL35A was detected by immunohistochemical staining and western blot analysis. The Celigo cell counting assay was used to assess cell proliferation. Both the wound healing assay and the transwell assay were conducted to evaluate cell migration. Flow cytometric analysis was utilized to detect cell apoptosis and cell cycle. A mouse xenograft model was constructed for in vivo experiments.

Results: The results demonstrated that RPL35A expression was abundantly up-regulated in GC and positively related to tumor infiltrate. In addition, RPL35A knockdown could significantly suppress cell proliferation, migration, enhance apoptosis and arrest cell cycle. The in vivo study also verified the inhibitory effects of RPL35A knockdown on GC tumorigenesis.

Conclusions: The above mentioned results indicated that the knockdown of RPL35A might be a considerable therapeutic strategy for the treatment of gastric cancer.

摘要：

背景:RPL35A已被報(bào)道為腫瘤血管生成的生物標(biāo)志物。然而，關(guān)于RPL35A在胃癌(GC)中的表達(dá)水平及其功能重要性的研究很少。

方法:采用免疫組化染色和western blot方法檢測(cè)RPL35A蛋白表達(dá)水平。采用Celigo細(xì)胞計(jì)數(shù)法評(píng)估細(xì)胞增殖情況。采用傷口愈合實(shí)驗(yàn)和transwell實(shí)驗(yàn)來(lái)評(píng)估細(xì)胞遷移。流式細(xì)胞術(shù)檢測(cè)細(xì)胞凋亡和細(xì)胞周期。建立小鼠異種移植物模型進(jìn)行體內(nèi)實(shí)驗(yàn)。

結(jié)果:結(jié)果顯示RPL35A在胃癌中表達(dá)量顯著上調(diào)，與腫瘤浸潤(rùn)呈正相關(guān)。RPL35A敲低可顯著抑制細(xì)胞增殖、遷移、促進(jìn)細(xì)胞凋亡、阻滯細(xì)胞周期。體內(nèi)研究也證實(shí)了RPL35A敲低對(duì)GC腫瘤發(fā)生的抑制作用。

結(jié)論:上述結(jié)果提示，下調(diào)RPL35A可能是治療胃癌的一種有效的治療策略。

該論文中，AGS和MGC-803細(xì)胞的體外培養(yǎng)是使用Ausbian特級(jí)胎牛血清完成的。欲了解或購(gòu)買Ausbian特級(jí)胎牛血清可以聯(lián)系北京締一生物400-166-8600.